Intravenous immunoglobulin for treatment of toxic epidermal necrolysis

American Journal of the Medical Sciences

Volumn 329, Issue 2, 2005, Pages 95-98

  Nasser, Maher ^a   Bitterman Deutsch, Ora ^a   Nassar, Faris ^a  

^a WESTERN GALILEE HOSPITAL   (Israel)

Author keywords

Intravenous immunoglobulin; Toxic epidermal necrolysis

Indexed keywords

AEROVENT; ALLOPURINOL; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CALCIUM ALGINATE; CARBAMAZEPINE; CILAZAPRIL; DIBENZAZEPINE DERIVATIVE; DIPYRONE; FLUCONAZOLE; GLUCAGON; HYDROCORTISONE; IMIPENEM; IMMUNOGLOBULIN; IPRATROPIUM BROMIDE; NYSTATIN; PENICILLIN G; POVIDONE IODINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SALBUTAMOL; TRIETHANOLAMINE SALICYLATE; VANCOMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ASTHMA; CASE REPORT; CLINICAL FEATURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GOUT; HUMAN; HYPOTHYROIDISM; IMMUNOTHERAPY; TOOTH PAIN; TOXIC EPIDERMAL NECROLYSIS;

EID: 13844267551     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000441-200502000-00007     Document Type: Article

References (36)

1. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalded skin. Br J Dermatol 1956;68:355-61.
2. Roujeau JC, Stern RS. Severe cutaneous adverse reactions to drugs. N Engl J Med 1994;331:1272-85.
3. Bastuji-Gorin S, Rzany B, Stern RS, et al. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiform. Arch Dermatol 1993;129:92-6.
4. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987;123:1160-5.
5. Schulz JT, Sheridan RL, Ryan CM, et al. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000;21:199-204.
6. Roujeau JC, Stern RS. Severe adverse cutaneous reaction to drugs. N Engl J Med 1994;331:1272-85.
7. Westly ED, Wechsler HL. Toxic epidermal necrolysis: granulocytic leukopenia as a prognostic indicator. Arch Dermatol 1984;120:721-6.
8. Khoo AK, Foo CL. Toxic epidermal necrolysis in a burn centre: a 6-year review. Burns 1996;22:275-8.
9. Bastuji-Garin S, Fouchard N, Bertocchi M, et al. SCORTEN: a severity-of illness score for toxic epidermal necrolysis, J Invest Dermatol 2000;115:149-53.
10. McGee T, Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 1998;102:1018-22.
11. Yarbrough DR 3rd. Experience with toxic epidermal necrolysis treated in a burn center. J Burn Care Rehabil 1996;17:30-3.
12. Heimbach DM, Engrav LH, Marvin JA, et al. Toxic epidermal necrolysis: a step forward in treatment. JAMA 1987;257:2171-5.
13. Parsons JM. Toxic epidermal necrolysis. Int J Dermatol 1992;31:749-68.
14. Spielberg SP, Gordon GB, Blake DA, et al. Predisposition to phenytoin hepatotoxicity assessed in vitro. N Engl J Med 1981;305:722-7.
15. Shear NH, Spielberg SP, Grant DM, et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986;105:179-84.
16. Prins C, Kerdel FA, Padilla RS, et al. Treatment of toxic epidermal necrolysis with high dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003;139:26-32.
17. Trent J, Kirsner RS, Romanelli P, et al. Analysis of intravenous immunoglobulin for treatment of toxic epidermal necrolysis using SCORTEN. Arch Dermatol 2003;1398:39-43.
18. Ruocco V, Bimonte D, Luongo C, et al. Hyperbaric oxygen treatment of toxic epidermal necrolysis. Cutis 1986;38:267-71.
19. Sakellariou G, Koukoudis P, Karpouzas J, et al. Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN). Int J Artif Organs 1991;14:634-8.
20. Goulden V, Goodfield MJ. Recombinant granulocyte colony-stimulating factor in the management of toxic epidermal necrolysis. Br J Dermatol 1996;135:305-6.
21. Roujeau JC, Chosidow O, Saiag P, et al. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990;23:1039-58.
22. Halebian PH, Corder VJ, Madden MR, et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986;204:503-12.
23. Wolkenstein P, Charue D, Laurent P, et al. Metabolic predisposition to cutaneous adverse drug reactions: role in toxic epidermal necrolysis caused by sulfonamides and anticonvulsants. Arch Dermatol 1995;131:544-51.
24. Villada G, Roujeau JC, Clerici T, et al. Immunopathology of toxic epidermal necrolysis, keratinocytes, HLA-DR expression, Langerhans cells, and mononuclear cells: an immunopathologic study of five cases. Arch Dermatol 1992;128:50-3.
25. Correia O, Delgado L, Ramos JP, et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis: further evidence of CD8+ lymphocyte involvement. Arch Dermatol 1993;129:466-8.
26. Guillaume JC, Roujeau JC, Revuz J, et al. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell syndrome). Arch Dermatol 1987;123:1166-70.
27. Rzany B, Correia O, Kelly JP, et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999;353:2190-4.
28. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of cd35 with human intravenous immunoglobulin. Science 1998;282:490-3.
29. Werhrli P, Viard I, Bullani R, et al. Death receptors in cutaneous biology and disease. J Invest Dermatol 2000;115:141-8.
30. Lebargy F, Wolkenstein P, Gisselbreacht M, et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 1997;23:1237-44.
31. Lehman SS. Long-term ocular complication of Stevens-Johnson syndrome. Clin Pediatr (Phila) 1999;38:425-7.
32. Jordan MH, Lewis MS, Jeng JG, et al. Treatment of toxic epidermal necrolysis by burn units: another market or another threat? J Burn Care Rehabil 1991;12:579-81.
33. Demling RH. Burns. N Engl J Med 1985;313:1389-98.
34. Patterson R, Miller M, Kaplan M, et al. Effectiveness of early therapy with corticosteroids in Stevens Johnson syndrome: experience with 41 cases and a hypothesis regarding pathogenesis. Ann Allergy 1994;73:27-34.
35. Moudgil A, Porat S, Brunnel P, et al. Treatment of Steven-Johnson syndrome with pooled human intravenous immune globulin. Clin Pediatr (Phila) 1995;34:48-51.
36. Heng MC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis: clinical and pathophysiologic aspects. J Am Acad Dermatol 1991;25:778-86.